Guidelines and Consensus Statements

Section Edited by Robert L. Ferris, MD, PhD This section highlights current or evolving clinical practice guidelines and consensus statements, and provides guidance to enhance clinical decision making in the field of cancer immunotherapy.

Showing results 51 - 53 of 53

Sorted by most recent

TitleAuthorDate

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Douglas G. McNeel, Neil H. Bander, Tomasz M. Beer, Charles G. Drake, Lawrence Fong, Stacey Harrelson, Philip W. Kantoff, Ravi A. Madan, William K. Oh, David J. Peace, Daniel P. Petrylak, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. SlovinSee the full list of authors

20 December 2016

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Michael Boyiadzis, Michael R. Bishop, Rafat Abonour, Kenneth C. Anderson, Stephen M. Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen Van Besien, P. Leif Bergsagel, Ivan Borrello, Joshua Brody, Jill Brufsky, Mitchell Cairo, Ajai ChariSee the full list of authors

20 December 2016

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Brian I. Rini, David F. McDermott, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas Hutson, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. QuinnSee the full list of authors

15 November 2016

Prev 1 2 3 4 56